American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2021, 9(9), 438-440
DOI: 10.12691/ajmcr-9-9-1
Open AccessCase Report

An Unusual Case of Secondary Pulmonary Alveolar Proteinosis in Recently Diagnosed Anti-MDA5 Positive Amyopathic Dermatomyositis

Komal Ejaz1, , Mousa Thalji1, Muhammad Ali Raza2 and Hassan Awais2

1Internal Medicine, The Wright Center For Graduate Medical Education, Scranton, PA, USA

2Internal Medicine, Conemaugh Memorial Medical Center/Temple University, Johnstown, PA, USA

Pub. Date: May 17, 2021

Cite this paper:
Komal Ejaz, Mousa Thalji, Muhammad Ali Raza and Hassan Awais. An Unusual Case of Secondary Pulmonary Alveolar Proteinosis in Recently Diagnosed Anti-MDA5 Positive Amyopathic Dermatomyositis. American Journal of Medical Case Reports. 2021; 9(9):438-440. doi: 10.12691/ajmcr-9-9-1

Abstract

Amyopathic dermatomyositis (AMD) is a subtype of dermatomyositis characterized by more prominent involvement of the skin rather than muscle and often positive for melanoma differentiation-associated gene 5 (MDA-5) antibodies. The most frequent pulmonary involvement in MDA-5 positive AMD is nonspecific interstitial pneumonia. However, rare cases of pulmonary alveolar proteinosis (PAP) have also been reported. Here, we present a case of a 28-year-old male who was recently diagnosed with AMD presenting with shortness of breath and dry cough was eventually diagnosed with secondary pulmonary alveolar proteinosis. This case underscores the multidisciplinary approach and diagnostic challenges associated with the diagnosis of PAP secondary to the rarity of the condition.

Keywords:
Amyopathic Dermatomyositis secondary pulmonary alveolar proteinosis PAP MDA-5

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Bendewald MJ, Wetter DA, Li X, Davis MD: Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010, 146: 2630.
 
[2]  Kumar A, Abdelmalak B, Inoue Y, Culver DA: Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. Lancet Respir Med.. 2018, 6: 554-65.
 
[3]  Ikeda, S., Arita, M., Morita, M. et al.: Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?. BMC Pulm Med.. 2015, 159.
 
[4]  Miller FW: Polymyositis and dermatomyositis.. In: Goldman L and Ausiello D, eds, Cecil textbook of medicine. 22nd edn. Philadelphia: Saunders. 2004, 1680: 4.
 
[5]  Ikeda S, Arita M, Misaki K et al.: Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Springerplus. 2015, 4: 240.
 
[6]  Marie I, Hatron PY, Hachulla E et al.: Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol. 1998, 25: 1336-43.
 
[7]  Cordonnier CA, Fleury-Feith JO, Escudier ES et al.: Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med. 1994, 149: 788-94.
 
[8]  Tomonari A, Shirafuji N, Iseki T et al.: Acquired pulmonary alveolar proteinosis after umbilical cord blood transplantation for acute myeloid leukemia. Am J Hematol. 2002, 70: 154-7.
 
[9]  Inoue Y, Trapnell BC, Tazawa R et al.: Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 20081, 177: 752-62.
 
[10]  Suzuki T, Trapnell BC: Pulmonary alveolar proteinosis syndrome. Clin Chest Med. 2016, 37:431-40.
 
[11]  Shah PL, Hansell D, Lawson PR et al.: Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax. 2000, 55:67-77.
 
[12]  Claypool WD, Rogers RM, Matuschak GM: Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis). Chest. 1984, 85:550-8.
 
[13]  Tazawa R, Trapnell BC, Inoue Y et al.: Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med.. 2010, 181: 1345-54.
 
[14]  Borie R, Debray MP, Laine C et al.: Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J.. 2009, 1: 1503-6.